	Post-traumatic growth in liver cirrhosis patients: a cross-sectional study on the roles of psychological resilience and fear of progression based on the stress-coping theory. Front Psychol Wang Y, Kong F, Zhang Q, Wang Q, Yang L. PMID: 41884548 [PubMed]
	Excess mortality from cirrhosis by neighbourhood deprivation, aetiology, and clinical presentation: a Swedish register-based cohort study. EClinicalMedicine Vaz J, Lazarus JV, Hagström H, Strömberg U. PMID: 41884492 [PubMed]
	Risk factors for the development of cirrhosis within 1-year in non-cirrhotic patients with HBV- related acute-on-chronic liver failure. Front Med (Lausanne) Wang W, Wang X, Wu Y, Zou H, Xu M, Chen Y. PMID: 41884146 [PubMed]
	Systematic Review: Imaging-Based Morphological Criteria for Liver Cirrhosis-A Call to Standardise. Aliment Pharmacol Ther Lim MC, Quek EJW, Chan TYH, Teng M, Ng CH, Gnanavelou M, Chen VL, Fallowfield JA, Zhang H, Noureddin M, Ko D, Nah B, Takahashi H, Siddiqui MS, Lai JC, Wijarnpreecha K, Zheng M, Kumar R, Rattananukrom C, Kow A, Syn N, Wang YC, Nakajima A, Tang A, Lee JM, Huang DQ, Muthiah M, Sirlin CB. PMID: 41882492 [PubMed - as supplied by publisher]
	Clinical prediction of the mortality for acute kidney injury in decompensated cirrhosis. Sci Rep Pan XY, Yang HL, Du T, Wu JH, Qin FY, Yu B, Liang ZY, Luo W. PMID: 41882042 [PubMed - as supplied by publisher]
	Pathological analysis of liver and cyst wall in prenatally diagnosed choledochal cysts in children. Eur J Pediatr Yin T, Liu W, Chen X, Chen S, Diao M, Li L. PMID: 41879933 [PubMed - indexed for MEDLINE]
	Hsa_circ_0000711 can serve as a novel biomarker for primary biliary cholangitis by promoting disease progression through the regulation of miR-185-5p and NFATc3. RNA Biol Lu W, Li W, Wang P, Cong P, Wang Z, Gao W, Sun G, Liu M. PMID: 41879109 [PubMed - indexed for MEDLINE]
	Family Resilience Among Families of Patients With Liver Cirrhosis and Its Influencing Factors. Gastroenterol Nurs Xu J, Sun S, Li Y, Wang L. PMID: 41875339 [PubMed - indexed for MEDLINE]
	Cost-utility and budget impact analyses of significant fibrosis detection in individuals with metabolic syndrome or obesity in Thailand. PLoS One Kositamongkol C, Tantiyavarong P, Ratanatawan A, Sripongpun P, Mahawithitwong P, Kositamongkol P, Saokaew S, Phisalprapa P. PMID: 41871114 [PubMed - indexed for MEDLINE]
	Long-term effects of L-carnitine on hyperammonemia and hepatic encephalopathy in patients with liver cirrhosis: a multicenter retrospective study. Eur J Gastroenterol Hepatol Tani J, Moriya A, Tomonari T, Ogawa C, Tsutsui A, Morishita A, Sakamoto T, Tai H, Yano R, Nakahara M, Oura K, Tadokoro T, Fujita K, Mimura S, Himoto T, Tanaka H, Imado R, Manabe T, Takuma K, Nagano T, Takaguchi K, Takayama T, Kobara H. PMID: 41870958 [PubMed - as supplied by publisher]
	Screening of Hepatocellular Carcinoma in Hepatic Cirrhosis Patients by a Novel Blood-Based Multi-Omics Test. Technol Cancer Res Treat Chen L, Liu J, Long M, Hu P. PMID: 41869803 [PubMed - indexed for MEDLINE]
	Reassessing the Baveno based strategy in China: a cost-effectiveness analysis of screening for high-risk varices in cirrhosis. Front Public Health Su S, Luo J, Li C, Yang C, Yang J, Ding D, Liu X, Guo G, Han Y. PMID: 41869588 [PubMed - indexed for MEDLINE]
	Nanomedicine-Driven Modulation of Signaling Pathways in Hepatic Fibrosis. Int J Nanomedicine Ji P, Li Y, Jin Y, Dong Y, Li L, Ma Z, Liu L, Zhang Y, Ren Z. PMID: 41869405 [PubMed - indexed for MEDLINE]
	The Dual-Faceted Role of Metal-Based Nanomaterials in Hepatic Fibrosis Therapy. Int J Nanomedicine Mao Y, Gong Y, Bai X. PMID: 41869402 [PubMed - indexed for MEDLINE]
	Identification of potential biomarkers and therapeutic targets for liver cirrhosis based on Mendelian randomization and machine learning. Biochem Biophys Rep Zhang K, Chen T, Jia Z, Zhao J, Huang N. PMID: 41869075 [PubMed]
	Nomogram Using Taurocholic Acid, Age, and Albumin to Predict HBV-Related Cirrhosis/HCC in CHB Patients. J Hepatocell Carcinoma Zhang X, Zheng L, Zheng W, Shi J, Yu S, Liu H, Feng H, Yu Z. PMID: 41868263 [PubMed]
	HCC Is the Predominant Liver-Related Event in MASLD: 2-Step Non-Invasive Algorithms to Stratify Risk in Non-Cirrhotic Patients. J Hepatocell Carcinoma Indre MG, Stefanini B, Boe M, Capelli R, Chen R, Abbati C, Santangeli E, Salamone A, Girolami F, Tovoli F, Morelli MC, Piscaglia F, Ferri S, Ravaioli F. PMID: 41868260 [PubMed]
	Ammonia measurement in cirrhosis: International Delphi consensus recommendations from ISHEN. J Hepatol Ballester MP, Gallego-Durán R, Shalimar, Thomsen KL, Karvellas CJ, Dasarathy S, Shawcross DL, Thabut D, Chen J, Rose CF, Jalan R, Delphi panellists. PMID: 41865800 [PubMed - as supplied by publisher]
	Atorvastatin reduces recurrent decompensation events in advanced cirrhosis in a randomized placebo-controlled trial. Sci Rep Glal KAM, El-Haggar SM, Abdel-Salam SM, Mostafa TM. PMID: 41865069 [PubMed - in process]
	Association of nonselective Î² blockers with the development of hepatocellular carcinoma in liver cirrhosis: a meta-analysis. Ann Hepatol Xu Y, Wang X, Li X, Zhao Q, Xu X. PMID: 41864541 [PubMed - as supplied by publisher]

Articles 1 - 20 / 38210

Page 1 of 1911



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy